What were Amgen's fourth-quarter financial results?

Amgen reported fourth-quarter financial results that exceeded Wall Street expectations, with revenue of $9.9 billion and strong sales driven by drugs like Repatha.

How did Amgen's drug sales perform in the fourth quarter?

Cholesterol drug Repatha sales jumped 44% to $870 million, while eye disease drug Tepezza fell 1% and arthritis drug Enbrel dropped 48%.

What is Amgen's financial outlook for 2026?

Amgen forecasts 2026 adjusted earnings per share between $21.60 and $23.00, with projected revenue between $37 billion and $38.4 billion.

Home / Business and Economy / Amgen Surges on Strong Q4 Earnings Beat

Amgen Surges on Strong Q4 Earnings Beat

4 Feb

•

Summary

Amgen exceeded Q4 revenue and EPS expectations.
Cholesterol drug Repatha sales jumped 44%.
Company anticipates positive 2026 financial outlook.

Amgen announced fourth-quarter financial results that surpassed analyst expectations, with overall revenue climbing 9% year-over-year to $9.9 billion. The company's adjusted earnings per share also exceeded forecasts. This performance was bolstered by a 10% rise in product sales volume, despite a 4% decrease in net prices.

Key to the quarter's success was a 44% surge in sales for the cholesterol drug Repatha, reaching $870 million. However, sales of the eye disease drug Tepezza saw a 1% decline, and the arthritis drug Enbrel experienced a significant 48% drop in sales. Amgen is actively pursuing future growth with six Phase 3 trials for its experimental obesity drug MariTide and is also testing another weight-loss candidate, AMG513.

The company projects 2026 adjusted earnings per share between $21.60 and $23.00, with revenue forecasts between $37 billion and $38.4 billion, indicating confidence in sustained performance.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.